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Abstract
Background: Rectal cancer surgery is accompanied with high morbidity and poor long term functional outcome.
Screening programs have shown a shift towards more early staged cancers. Patients with early rectal cancer can
potentially benefit significantly from rectal preserving therapy. For the earliest stage cancers, local excision is
sufficient when the risk of lymph node disease and subsequent recurrence is below 5 %. However, the majority of
early cancers are associated with an intermediate risk of lymph node involvement (5–20 %) suggesting that local
excision alone is not sufficient, while completion radical surgery, which is currently standard of care, could be a
substantial overtreatment for this group of patients.
Methods/Study design: In this multicentre randomised trial, patients with an intermediate risk T1-2 rectal cancer,
that has been locally excised using an endoluminal technique, will be randomized between adjuvant
chemo-radiotherapylimited to the mesorectum and standard completion total mesorectal excision (TME). To strictly
monitor the risk of locoregional recurrence in the experimental arm and enable early salvage surgery, there will be
additional follow up with frequent MRI and endoscopy. The primary outcome of the study is three-year local
recurrence rate. Secondary outcomes are morbidity, disease free and overall survival, stoma rate, functional outcomes,
health related quality of life and costs. The design is a non inferiority study with a total sample size of 302 patients.
Discussion: The results of the TESAR trial will potentially demonstrate that adjuvant chemoradiotherapy is an
oncological safe treatment option in patients who are confronted with the difficult clinical dilemma of a radically
removed intermediate risk early rectal cancer by polypectomy or transanal surgery that is conventionally treated with
subsequent radical surgery. Preserving the rectum using adjuvant radiotherapy is expected to significantly improve
morbidity, function and quality of life if compared to completion TME surgery.
Trial registration: NCT02371304, registration date: February 2015
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Background
The introduction of population based screening pro-
grams for colorectal cancer is expected to cause a shift
towards more early stage carcinoma’s, as shown in the
United Kingdom [1]. Radical rectal surgery (i.e. low an-
terior resection (LAR) or abdominoperineal resection
(APR)) is accompanied with high operative morbidity of
36 % and is associated with a significant negative impact
on functional outcome and quality of life [2–4]. More
than 50 % of patients experience some form of faecal in-
continence with a negative impact on quality of life.
Urinary incontinence or retention and sexual dysfunc-
tion are common [2, 5–7]. Furthermore, patients after
total mesorectal excision (TME) are confronted with
stoma related difficulties, morbidity and subsequent haz-
ards from stoma reversal in those with protected low
anastomoses. In the Dutch TME-trial, 19 % of patients
did not have a reversal of a temporary stoma after LAR
and the overall long term or permanent stoma rate was
40 % [8]. After APR, up to 40 % of patients experience
perineal wound complications. Long-term discomfort
after APR is related to stoma and stoma appliance-
related complications, occurring in up to 66 % [9]. The
disadvantages of radical surgery have been acceptable in
the pursuit of oncological control. However, early stage
cancer might be amenable to cure by local excision with
avoidance of radical surgery with its negative impact in a
significant proportion of patients [10]. Local excision
alone has only been considered oncological safe for low
risk T1 rectal cancer, which may be defined as well/
moderately differentiated without lymphatic or vascular
invasion and excised with at least 1 mm margin. In case of
any unfavourable histological characteristic, there is a sub-
stantial increase in the risk of lymph node metastases with
impaired oncological outcome after local excision alone,
requiring completion total mesorectal excision (TME)
[11]. Histological characteristics which are associated with
increased risk of local recurrence are: poor differentiation,
deep submucosal infiltration, lymphatic or vascular
invasion, SM3 and tumour size > 5 cm for pT1 or > 3 cm
for pT2 [11, 12].
Early rectal cancer (T1 and T2) with intermediate risk
for recurrence make up to 75 % of locally excised rectal
cancer, and present a management dilemma for patient,
surgeon and oncologist. These patients could be treated
with additional chemo-radiotherapy, thereby preserving
their rectum which likely has a positive impact on
function and quality of life (HRQoL). Additional chemo-
radiotherapy in the intermediate risk group has a poten-
tial to decrease the risk of local recurrence by sterilizing
mesorectal lymph nodes in the vicinity of the excised
tumour that may harbour (micro)metastasis. Current
evidence on rectal preserving treatment options after
local excision is limited, because of small sized
retrospective studies with several methodological prob-
lems. Characteristics of included patients, surgical tech-
nique of local excision, and reported local recurrence
rates and survival after adjuvant chemoradiotherapy for
pT1-T2 carcinomas are highly variable [13–18]. We con-
ducted a systematic review of all these studies, showing
poor quality of the selected studies with lack of rando-
mised data (Borstlap et al.). A relatively high pooled
weighted average of local recurrence rate of 14 % after
adjuvant radiotherapy was found, probably related to in-
clusion criteria that were not confined to an intermedi-
ate risk group. Only two of the 14 included studies in
the review consisted of a patient population that all had
clear resection margins [19, 20]. Their pooled average of
6 % recurrence after adjuvant chemoradiotherapy ther-
apy is low, but the sample size (n = 27) was too small to
draw any conclusion. Using strict patient selection based
on MRI imaging to exclude patients with suspicious
lymph nodes and pathological assessment of the excised
tumour, adjuvant (chemo)radiotherapy is potentially a
valid option as curative completion treatment for radic-
ally excised pT1 and small pT2. Additionally, improve-
ments in MRI and advanced endoscopic imaging will
enable careful follow-up and early detection of locore-
gional recurrent disease, allowing for early salvage sur-
gery that offers acceptable oncological outcome [21].
Therefore, there is an urgent need to define a new
treatment approach for patients who are confronted
with invasive growth in a locally excised rectal lesion
with intermediate risk of lymph node metastases. Such
an approach should result in an optimal balance be-
tween treatment related morbidity and oncological con-
trol for these early stage carcinomas. A multicentre
randomised controlled trial with strict inclusion criteria
based on tumour characteristics and an intensive follow-
up schedule in the rectal preserving treatment arm could
provide the much needed evidence on oncologic outcome
after adjuvant chemoradiotherapy for locally excised rectal
cancer compared to standard completion TME.
Methods/Design
The main objective of this multicentre randomised con-
trolled trial is to determine the optimal treatment strat-
egy for patients with a locally excised rectal lesion
revealing an early stage rectal cancer with post excision
pathology predicting intermediate (5–20 %) risk of re-
currence. The patients will be randomised, after local
excision, between either adjuvant chemoradiotherapy or
standard completion TME surgery.
The TESAR trial hypothesizes that local excision com-
bined with adjuvant chemoradiotherapy and close-
surveillance with the possibility of early salvage surgery
is non-inferior to completion TME in terms of local
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recurrence and superior in terms of treatment related
morbidity, functional outcome, and HRQoL.
All pathology specimens of potentially eligible patients
will be centrally revised by one pathologist in order to
exclude inter-observer bias. The patient who meets all
the inclusion criteria without any of the exclusion cri-
teria will be given information about the proposed trial.
The patient will have at least three days to decide upon
study participation. Randomization will be performed by
a central automated randomization system using the
trial website, with stratification for age (75- and 75+),
ASA (I and II+) classification, initial treatment (full
thickness excision and endoscopic excision) and tumour
classification (high risk T1 and low risk T2). The treat-
ment, either adjuvant chemo-radiotherapy or completion
TME surgery, should start within 4–8 weeks from ran-
domisation. Randomisation will be performed in random
blocks of sizes and 4.
The primary aim of the TESAR-Trial:
 To compare rectal preserving therapy (local excision
followed by adjuvant chemoradiotherapy) with
completion TME surgery in terms of 3-year
locoregional recurrence rate.
Secondary aims of the study are:
 To compare treatment related morbidity between
the study arms, both short and long-term.
 To determine 3-year and 5-year disease free survival
and overall survival after both treatment strategies.
 To determine stoma-free survival at one, three and
five years for both groups of patients.
 To investigate the impact of organ preserving
therapy on HRQol and functional outcomes
compared to radical surgery.
 Determining cost-effectiveness of rectal preserving
therapy with intensified follow-up using MRI and
endoscopy.
Study procedures
Since the control arm consists of completion TME
which will remove the mesorectum, the investigational
arm consists of chemoradiotherapy which is primarily
targeted at the mesorectum without expansion to pelvic
sidewall and lymph nodes along the iliac vessels. This is
based on the hypothesis that potential lymph node me-
tastases are located close to the primary tumour site in
these early stage cancers. Adapting radiation fields that
are normally used in more advanced rectal cancer limits
toxicity based on a patient tailored approach according
to estimated recurrence risks. Patients will receive
25×1.8 Gray, 5 days a week, combined with Capecitabine
825 mg/m2 twice a day, which will not be continued
during the weekends. The treatment in both study arms
should start between 4-8 weeks after local excision.
Patients treated with adjuvant chemoradiotherapy in the
experimental arm will receive an intensified follow-up
schedule with four extra pelvic MRI’s and three extra
sigmoidoscopies in addition to routine follow-up accord-
ing to the Dutch colorectal cancer guideline, while
control patients undergo routine follow-up with one
additional pelvic MRI at 24 months (see Fig. 1).
Patient population
Patients who are diagnosed with early rectal cancer that
was locally excised with tumour free margins (≥1 mm)
and a carcinoma within 10 cm from the anal verge are
informed about the TESAR trial if histopathology reveals
the following characteristics: pT1 with a diameter of
3–5 cm, or pT1 with a maximum diameter of 3 cm and
at least poor differentiation and/or lymphatic and/or
venous invasion and/or SM3 invasion depth, or a pT2,
maximum size 3 cm, well/moderately differentiated and
without lymphatic or venous invasion (Fig. 2). Any endo-
luminal technique for local excision may be included
(TEM, TAMIS, TSPM, EMR, ESD or polypectomy). A
central review of the pathology will be performed in order
to verify the histological inclusion criteria. Furthermore,
clinical nodal status should be N0 by pelvic MRI. In order
to prevent overstaging by post-excision MRI in these early
rectal cancers, mesorectal and extra-mesorectal lymph
nodes with a size smaller than 10 mm will be interpreted
as benign independent of their morphologic features.
Other inclusion criteria are absence of distant metastasis
by CT thorax/abdomen, age > 18 years, life expectancy of
at least 12 months, WHO performance status 0–2, and
written informed consent.
Patients are excluded from the study or registry in case of
a proximal rectal cancer (>10 cm from the anal verge or re-
quiring partial mesorectal excision), not fulfilling pathology
or imaging inclusion criteria, previous pelvic irradiation,
concomitant malignancies within past 5 years, or if patients
are unfit for subsequent chemoradiotherapy or surgery.
Early rectal carcinoma’s with pathological features
showing low risk T1 (<5 cm, well differentiated, no
lymphatic or vascular invasion) or high risk T2 (>3 cm
and/or poorly differentiated and/or lymphatic or vascu-
lar invasion) will be asked for registration only and will
be asked to sign informed consent to collect to use the
paraffin specimen for translational studies.
Outcome parameters
Loco-regional recurrence, morbidity, disease free survival,
stoma free survival and overall survival will be assessed by
regular follow-up at 3, 6, 9, 12, 18, 24, 36, 48 and
60 months post-operatively. Morbidity will be assessed
using the Comprehensive Complication Index (CCI) for
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the patients that undergo TME surgery and the NCI
CTCAE Toxicity Criteria (v4) for patients in the adjuvant
chemoradiotherapy arm [22]. Health related quality of life
and functional outcomes will be measured using the EQ-
5D, EORTC QLQ C29 & C30 and the LARS score. Pos-
sible advantage of the new rectal preserving treatment in
cost per quality of life adjusted life years using the EQ5D
score will be analysed. The total costs will be assessed by
summing the procedure related costs, in hospital stay
costs, re-intervention and morbidity related costs and
time to return to work will be calculated in loss of work
days, which can be converted to costs.
Follow-up
Patients in the intervention arm will receive an intensified
follow-up schedule to facilitate an early salvage procedure
Fig. 1 Study flowchart
Fig. 2 Inclusion characteristics
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in case of recurrence. Patients will have an additional clin-
ical evaluation including digital rectal examination at 3
and 9 months and a pelvic MRI will be performed at
6,18,36 and 60 months. Besides routine colonoscopy at 12
and 48 months according to the national guideline, three
additional sigmoidoscopies are performed at 6, 24 and
36 months. Patients in the control arm will receive one
additional MRI, 2 years after local excision. The follow-up
schedule is presented in Fig. 3.
Sample size
The trial is designed as a non-inferiority trial. The
expected percentage of patients who are free of local
recurrence after a three-year follow-up is 98 % in the
control group and 96 % in the study group. The differ-
ence in percentage of recurrence free patients between
standard treatment and experimental treatment may not
be larger than 7 %. Hence, the experimental treatment is
non-inferior if at least 91 % of patients is free of local
recurrence. This 91 % is seen as a worst case scenario
when adjuvant treatment has no influence on local re-
currence. Hypothesizing that the difference in percent-
age of patients with local recurrence may not be larger
than 7 %, with a one sided alfa, an 80 % power and a
drop-out of 5 % a sample size of 302 patients (151 per
group) is needed.
Data analysis
All analyses will be on an intention-to-treat basis [23].
Patients will be analysed as they are randomized
irrespective of the treatment actually received. The
intention-to-treat population will include all patients
who have given their informed consent and for whom
there is confirmation of successful allocation of a ran-
domisation number. To substantiate the interpretation
of the intention-to-treat analysis a per protocol analysis
will also be performed.
Statistical analyses will be performed using SPSS soft-
ware for Windows version 23 or higher. The one-sided
95 % confidence interval for the between-group differ-
ence in locoregional recurrence corresponds to the
lower limit of the two-sided 90 % confidence interval for
this difference (experimental minus standard). The organ
preserving treatment group (intervention) is considered
to be non-inferior to the standard treatment group if the
one-sided 95 % confidence for the difference in loco-
regional recurrence excludes a difference of minus 7 per-
centage points or farther away from zero in the same
direction. For the secondary outcomes as disease free
survival and overall survival two-sided 95 % confidence
intervals will be calculated. Appropriate summary de-
scriptive statistics will be determined for all secondary
endpoints at each visit using raw scores. To assess
morbidity the continuous scale of the Comprehensive
Complication Index [22] and the categorical Clavien-
Dindo classification will be used, for which appropriate
statistical tests will be undertaken (the Mann Whitney U
test, in case of non-normal distribution, and the Chi
squared test respectively). For continuous secondary
endpoints, either analysis of variance or analysis of
Fig. 3 Follow-up schedule TESAR trial. Green = extra follow-up moments for included patients in the rectal preserving group. The white x’s are
the follow-up moments according to national guideline. The blue star resembles the extra MRI in the control group
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covariance models will be used and where necessary, the
repeated measures procedure will be implemented. Qual-
ity of life data (e.g. EORTC-C30, EORTC-CR29, LARS
and EQ-5D) will be graphically represented across all time
points and analysed using a repeated measures analysis of
variance. All tests based on proportions will be analysed
using a logistic regression model with treatment as a fac-
tor and, where appropriate, other specified covariates.
Time-to-event will be analysed with use of Kaplan-Meier
Survival analysis and compared using the log-rank test.
The secondary efficacy analysis will be based on the Full
Analysis Set (FAS) and the per protocol populations. Sig-
nificance level is set at an alpha of 0.05 and no adjustment
will be made for testing multiple secondary outcomes.
Some significant findings are expected to occur by chance
so undue consideration will not be given to any particular
significant difference. Moreover, interpretation of the
results will be based on patterns of differences and in
conjunction with the results of the primary analyses.
Cost analysis
Unit costing of distinct health care resources will be in
accordance with national guidelines (<http://doc-
player.nl/6361834-Handleiding-voor-kostenonderzoek-
methoden-en-standaard-kostprijzen-voor-economische-
evaluaties-in-de-gezondheidszorg.html>). Cost data will
be derived as the product sum of health care volume data
and their respective unit cost. Observed health utilities
based on the EQ-5D health status profiles will be linked to
the lengths of the periods in between measurements to
derive QALYs. Incremental cost-effectiveness and cost-
utility analyses will be performed to calculate the extra
cost per additional patient free of local recurrence and the
extra costs per additional quality adjusted life year respect-
ively. Differences between groups will be assessed by cal-
culating 95 % confidence intervals for the mean
differences after non-parametric bootstrapping, drawing
at least 1000 samples of the same size as the original sam-
ple separately for each group and with replacement. A
cost-effectiveness acceptability curve will be drawn to
show the probability of adjuvant chemoradiotherapy being
cost- effective at willingness-to-pay values up to €80,000
per QALY. Single and multi-way sensitivity analyses will
be performed to study the robustness of these findings to
plausible changes in key unit costs and to alternative
health utility scoring algorithms [24]. Efficacy and cost
data will be discounted to account for time preference.
Discussion
The TESAR-Trial is the first multicentre randomised trial in
which patients with a pT1-T2 rectal carcinoma will be ran-
domised after local excision between rectal preserving adju-
vant chemoradiotherapy and completion TME. In this non-
inferiority trial we hypothesize that rectal preserving therapy
for early rectal cancer has similar oncological outcome with
significant improved morbidity, function and quality of life
compared to conventional radical surgery. The TESAR-Trial
is part of a national treatment consortium of multicentre
studies founded to create sufficient evidence on the best
treatment strategies for early rectal cancer.
The TREC trial from the UK (TEM and Radiotherapy
in Early Rectal Cancer) included patients with clinically
staged early (cT1-2N0M0) rectal cancer and randomised
between radical TME surgery and short course pre-
operative radiotherapy followed by TEM [REF]. The
CARTS phase II Dutch multicentre study prospectively
evaluated outcome after chemo-radiotherapy followed
by TEM for clinical T1-3N0M0 rectal cancer [25]. Re-
cently it was proposed to combine both initiatives in a
new protocol: the STARTREC trial. This study will be
conducted parallel to the TESAR trial in the Netherlands.
The STARTREC study will be randomizing between
intentional organ preserving therapy and radical TME
surgery. The STARTREC will include patients based on
imaging with the rectal cancer is still in situ. Patients with
small tumours staged as T1N0, less then 3 cm can still be
treated with initial local excision according to the national
guideline. If histopathology shows intermediate risk fea-
tures, they are eligible for the TESAR trial. Moreover, a
large proportion (up to 40 %) of rectal cancer is diagnosed
and discussed at the rectal cancer Multi-Disciplinary
Team meeting (MDT) after the patient has had an
endoluminal local- excision of a lesion that shows infiltra-
tive growth at pathological examination. These excisions
might have been polypectomies within the national
screening program or an excision of a clinically diagnosed
adenoma by for example TEM or EMR [11]. This sub-
group of patients can therefore not be included in the
STARTREC trial, but will be included in the TESAR. Both
TESAR and STARTREC use the same patient reported
outcome measurements allowing comparative combined
analysis. Together, potentially all patients with early rectal
cancer can be included and results from the randomised
trials will be powerful to answer which is the best treat-
ment strategy for patients with early rectal cancer.
Current literature on adjuvant chemoradiotherapy after
local excision consists of small cohort series which show
substantial variability in recurrence rates, ranging between
6 and 43 %, [15–19, 26–34]. Patient selection in these
series was often unclear, but often chemoradiotherapy was
chosen in patients refusing further surgery or being unfit
for completion TME despite they had an incomplete re-
section or high risk T2 rectal cancer. This explains the
relatively high recurrence rates in these series. Further-
more, a variety in adjuvant radiotherapy regimens was
used, and none of the studies reported a strict follow-up
schedule including digital rectal examination, MRI and
endoscopy to allow for early salvage treatment.
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Within the TESAR trial, strict pathological selection
criteria based on differentiation grade, lymphatic- or vas-
cular invasion and size of the tumour are used in order
to include only the intermediate risk group and to ex-
clude patients at high risk of local recurrence. Therefore
we expect that the risk of recurrence after adjuvant che-
moradiotherapy following local excision will be lower
than reported so far. Treatment related morbidity from
the chemoradiotherapy is expected to be lower than
earlier reported [25]. This is related to the radiation field
which is limited to the mesorectum and a lower total
dose of 45 Gy than generally applied in more advanced
rectal cancer. Additionally, concomitant chemotherapy
is only given on weekdays. This less intensive chemora-
diotherapy schedule is considered to be oncologically
save because only radically removed early rectal carcin-
omas are included. Nevertheless, patients in the rectal
preserving group of the TESAR are expected to have a
slightly higher risk of recurrence than the control group.
However, this increase is accepted due to the close
standardised follow up schedule which allows for early
salvage of recurrence. To ensure adequate patient inclu-
sion with the anticipated intermediate risk of recurrence,
all specimens of the locally excised tumours are centrally
reviewed before a patient can be included in the trial.
In conclusion, due to a shift towards more early staged
carcinomas shift and high morbidity of TME surgery,
there is an increasing need for less invasive treatment
approaches with acceptable oncological outcome. After
local excision has revealed a high risk T1 or low risk T2
carcinoma, adjuvant chemoradiotherapy could be an
oncological safe alternative for radical surgery, with po-
tential improvements in treatment related morbidity,
functional outcome and quality of life. This will pro-
spectively be evaluated in the randomised multicentre
TESAR trial.
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